To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant supports patient-prioritized Canadian research projects that address critical knowledge gaps in the diagnosis, treatment, and care of multiple myeloma and/or related plasma cell disorders. These gaps were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP was a collaborative initiative involving Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and followed established PSP methodologies set out by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, Myeloma Canada intends to contribute CDN $300,000 to this grant competition, with additional funding potentially available through partnerships. All grant awards are for CDN $150,000.
Applications will be accepted from April 16 – June 30, 2026. Funding decisions will be communicated to applicants in October 2026. The Principal Investigator must be a researcher at any career stage and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.
2026 Aldo Del Col Research Grant
To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant supports patient-prioritized Canadian research projects that address critical knowledge gaps in the diagnosis, treatment, and care of multiple myeloma and/or related plasma cell disorders. These gaps were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP was a collaborative initiative involving Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and followed established PSP methodologies set out by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, Myeloma Canada intends to contribute CDN $300,000 to this grant competition, with additional funding potentially available through partnerships. All grant awards are for CDN $150,000.
Applications will be accepted from April 16 – June 30, 2026. Funding decisions will be communicated to applicants in October 2026. The Principal Investigator must be a researcher at any career stage and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.